Literature DB >> 7226493

Effect of serum dilution on apparent unbound bilirubin concentration as measured by the peroxidase method.

C E Ahlfors.   

Abstract

I studied the effects of serum dilution and oxidation of albumin-bound bilirubin on the accuracy of results by the peroxidase method for assessing bilirubin-albumin binding. The apparent concentration of unbound bilirubin decreases with dilution of bilirubin-enriched serum or defatted-albumin solutions, the effect being more marked with serum. The decrease in apparent unbound bilirubin does not appear to be due to slow oxidation of albumin-bound bilirubin. Instead, the bilirubin-albumin complex has a much lower apparent dissociation rate constant (K-1) in serum (0.0033 [SD 0.0002] s-1) than in solutions of defatted-albumin (0.017 [SD 0.006] s-1), causing the dissociation of the complex to be rate-limiting when serum is analyzed at the currently recommended 40-fold dilution and peroxidase concentration (0.11 mu mol/L). In addition, dilution appears to enhance bilirubin binding by serum but not by defatted-albumin solutions. Decreasing the serum dilution and peroxidase concentration may significantly improve the accuracy of the peroxidase test. The actual correlation between clinical bilirubin toxicity and specific unbound bilirubin concentrations, however, remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7226493

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

Review 1.  The blood-brain barrier and bilirubin encephalopathy.

Authors:  R P Wennberg
Journal:  Cell Mol Neurobiol       Date:  2000-02       Impact factor: 5.046

2.  Effects of sample dilution, peroxidase concentration, and chloride ion on the measurement of unbound bilirubin in premature newborns.

Authors:  Charles E Ahlfors; Hendrik J Vreman; Ronald J Wong; G Jesse Bender; William Oh; Brenda H Morris; David K Stevenson
Journal:  Clin Biochem       Date:  2006-09-29       Impact factor: 3.281

3.  Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier.

Authors:  Kevin A Strauss; Charles E Ahlfors; Kyle Soltys; George V Mazareigos; Millie Young; Lauren E Bowser; Michael D Fox; James E Squires; Patrick McKiernan; Karlla W Brigatti; Erik G Puffenberger; Vincent J Carson; Hendrik J Vreman
Journal:  Hepatology       Date:  2020-02-05       Impact factor: 17.425

4.  Bilirubin binding by variant albumins in Yanomama Indians.

Authors:  F W Lorey; C E Ahlfors; D G Smith; J V Neel
Journal:  Am J Hum Genet       Date:  1984-09       Impact factor: 11.025

5.  Digital Microfluidic Platform to Maximize Diagnostic Tests with Low Sample Volumes from Newborns and Pediatric Patients.

Authors:  Rama S Sista; Rainer Ng; Miriam Nuffer; Michael Basmajian; Jacob Coyne; Jennifer Elderbroom; Daniel Hull; Kathryn Kay; Maithri Krishnamurthy; Christopher Roberts; Daniel Wu; Adam D Kennedy; Rajendra Singh; Vijay Srinivasan; Vamsee K Pamula
Journal:  Diagnostics (Basel)       Date:  2020-01-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.